Last reviewed · How we verify

NCT06321497

Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury

Recruiting now Last updated 20 March 2024
What this trial tests

trial testing Extracorporeal carbon dioxide removal in ARDS, Human in 15 participants. Currently enrolling.

Timeline
5 February 2024
Primary endpoint
28 February 2027
28 February 2028

Quick facts

Lead sponsorPeninsula Health
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment15
Start date5 February 2024
Primary completion28 February 2027
Estimated completion28 February 2028
Sites1 location across Australia

Drugs / interventions tested

Conditions studied

Sponsor

Peninsula Health

Who can join

18 and older, any sex, with ARDS, Human. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Lung protective ventilation with low tidal volumes and low driving pressure are known to reduce mortality in mechanically ventilated patients with acute respiratory failure. This reduction in mortality is known be due to reduction of ventilator induced lung injury that occurs due to high tidal volumes and high driving pressure. When receiving such mechanical ventilation, some patients develop hypercapnia and associated hypercapnic acidosis. Such patients have an increased risk of mortality. While the exact reasons for such increase in mortality is not known, it is recommended to minimise hypercapnia and hypercapnic acidosis during lung protective ventilation. Minimally invasive extracorporeal carbon dioxide removal (ECCO2R) devices are shown to reduce hypercapnia and hypercapnic acidosis. There are several devices that are currently available in the current clinical practice. However, the effect of these devices on reduction in ventilator induced lung injury is not clearly demonstrated. This study aims to assess the use of an ECCO2R device called Prismalung in reducing ventilator induced lung injury. PrismaLung is currently used in our intensive care unit. This assessment is done by measuring interleukins in bronchoalveolar lavage fluid and blood interleukin levels as well as clinical assessment including the reduction of driving pressure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Extracorporeal carbon dioxide removal

Trials testing the same drug.

Other recruiting trials for ARDS, Human

Currently open trials in the same condition.

Other Peninsula Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06321497.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing